calmangafodipir

Calmangafodipir is a synthetic small molecule that acts as a mimetic of human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant and iron-chelating properties. It is derived from mangafodipir, with most of the manganese replaced by calcium to improve safety and efficacy. Calmangafodipir scavenges oxygen free radicals such as superoxide anion, hydrogen peroxide, and hydroxyl radical, thereby protecting tissues from oxidative damage. Its primary clinical development has focused on preventing chemotherapy-induced peripheral neuropathy (CIPN), particularly in patients receiving oxaliplatin-based regimens for colorectal cancer. The drug has also received orphan designation for liver failure in Europe and is being investigated for paracetamol poisoning. Calmangafodipir was originally developed by PledPharma and further developed by Egetis Therapeutics[1][2][3][4][5][6].

Brand names

PledOxAladote

Other names

calmangafodipir (ca4mn(dpdp)5)tetracalcium monomanganese penta(dipyridoxyl diphosphate)calcium,n,n'-1,2-ethanediylbis(n-(3-hydroxy-2-methyl–5-(phosphonooxy)methyl)-4-pyridinyl)methyl)glycine) manganese complexes trisodium trihydrogen manganate